To the Editors: On May 2, 2007, the US Food and Drug Administration expanded black box
warnings of all antidepressant medications to include information about an increased risk of …

This study was undertaken to examine the long-term effectiveness and safety of switching to
sertraline from other selective serotonin reuptake inhibitors (SSRIs) in the treatment of non …

This study assessed the effect of general medical comorbidity on response to next-step
antidepressant treatments among subjects with major depressive disorder whose …

In 1990 a report appeared in the American Journal of Psychiatry1 concerning six patients
with a history of depression who developed “intense, violent suicidal preoccupation” during …

Despite a proliferation of pharmaceutical options for the treatment of major depression over
the past 20 years, reported remission rates among patients given antidepressants have …

Background Psychotic major depression is a clinical subtype of major depressive disorder. A
number of clinical studies have demonstrated the efficacy of the combination of an …

3. Discussion The time course of this symptom remission approximately 1 week after
fluoxetine discontinuation is strikingly consistent with the pharmacokinetics of fluoxetine …

To the Editor: It was dismaying to read the article by Jerome H. Markovitz, MD, MPH, et al.(1)
concerning platelet function in depressed subjects before and after sertraline treatment …

Venlafaxine, a novel antidepressant, selectively inhibits the neuronal reuptake of serotonin
and norepinephrine and is a weak reuptake inhibitor of dopamine. It has been reported to …